A systematic review and meta-analysis published on 29 August pooled nine randomised trials covering 6,239 adults with overweight or obesity but without diabetes, and found that injected semaglutide reduced a standard marker of inflammation by roughly 40% alongside the weight loss it is prescribed for. Serious adverse events were no more common than on placebo. … Read more
Eli Lilly reported on 23 July 2026 that retatrutide, an investigational triple hormone receptor agonist, met its primary endpoint in two further Phase 3 trials. Participants with obesity and type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks; those with severe obesity and established cardiovascular disease lost up … Read more
The FDA has approved a new indication for Mounjaro (tirzepatide): lowering the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes who are at high risk for them. Eli Lilly announced the approval on 28 August 2026. It is the first cardiovascular … Read more
Trial results describe what happens under close supervision with motivated volunteers. A study published in August in The Lancet Diabetes & Endocrinology asked a harder question: among 45,093 real patients with obesity and type 2 diabetes, how many actually hit a meaningful combined target a year after starting treatment? The answer for semaglutide was 3.0%. … Read more
The standard maintenance dose of Wegovy is 2.4 mg a week. STEP UP, a phase 3b randomised trial published in The Lancet Diabetes & Endocrinology, tested three times that — 7.2 mg — against both the standard dose and placebo over 72 weeks. Average weight loss was 20.7% on the high dose, 17.5% on 2.4 … Read more
The question people ask most often about these two drugs — which one works better — has a direct answer, and has had one since July 2025. In SURMOUNT-5, a trial that gave 751 adults either tirzepatide or semaglutide and followed them for 72 weeks, tirzepatide produced an average weight reduction of 20.2% against semaglutide’s … Read more